Northwest Biotherapeutics to Present at BIO CEO & INVESTOR CONFERENCE

Highlights Include Clinical and Corporate Updates, Striking Long-Term Data, and Lack of Toxicity, Low Cost and Simplicity of DCVax® Therapeutic Vaccines

News provided by

Northwest Biotherapeutics

Feb 14, 2011, 06:00 ET

BETHESDA, Md., Feb. 14, 2011 /PRNewswire/ -- Northwest Biotherapeutics (OTC Bulletin Board: NWBO) announced today that its Chair of the Board of Directors, Ms. Linda Powers, will give a corporate presentation at the 13th Annual Biotechnology Industry Organization's BIO CEO & Investor Conference being held February 14th, 2011 at 2:00 pm in the Conrad Room of the Waldorf Astoria Hotel in New York City.

Ms. Powers will provide a corporate and clinical update, including an update on NWBT's DCVax® therapeutic cancer vaccine for Glioblastoma multiforme, which is in a Phase II, randomized, double blinded, placebo controlled clinical trial. The update will include the striking long-term follow-up data from prior trials, the lack of toxicity, the ease of administration, the relatively low cost, the multi-product pipeline, and the high-yield manufacturing process for the Company's DCVax® cancer vaccine. The presentation will be web cast and can be accessed using: http://www.veracast.com/webcasts/bio/ceoinvestor2011/44110196.cfm

About Northwest Biotherapeutics

Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products that treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies, and on a cost-effective basis. The Company is developing dendritic cell-based vaccines. The Company's lead clinical trial is a 240-patient Phase II trial in newly diagnosed Glioblastoma multiforme ("GBM"), the most aggressive and lethal form of brain cancer. The Company also previously received clearance from the FDA for a 612-patient Phase III trial in prostate cancer, and clearance from the FDA for Phase I trials in five other cancers. The Company has also conducted a Phase I/II trial with DCVax® for recurrent metastatic ovarian cancer.

For further information about clinical sites and about the Company, please visit the Company's web site at www.nwbio.com.

Disclaimer

Statements made in this news release that are not historical facts, including statements concerning future treatment of patients with GBM using DCVax®-Brain and future clinical trials, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "expects," "believes," "intends," and similar expressions are intended to identify forward-looking statements. Actual results may differ materially from those projected in any forward-looking statement. Specifically, there are a number of important factors that could cause actual results to differ materially from those anticipated, such as the Company's ability to raise additional capital, risks related to the Company's ability to enroll patients in its clinical trials and complete the trials on a timely basis, the uncertainty of the clinical trials process, uncertainties about the timely performance of third parties, and whether the Company's products will demonstrate safety and efficacy. Additional information on these and other factors, including Risk Factors, which could affect the Company's results, is included in its Securities and Exchange Commission ("SEC") filings. Finally, there may be other factors not mentioned above or included in the Company's SEC filings that may cause actual results to differ materially from those projected in any forward-looking statement. You should not place undue reliance on any forward-looking statements. The Company assumes no obligation to update any forward-looking statements as a result of new information, future events or developments, except as required by securities laws.

SOURCE Northwest Biotherapeutics